CTLA4 and autoimmune disease: Although the autoimmune diseases against self-antigens were much milder and at later onset in PD-1/PD-L1/L2 deficient mice than in CTLA-4−/− mice, anti-PD-1 mAbs exhibited stronger antitumor effects than anti-CTLA-4 mAbs in tumor models (10, 25).